SI9300421A - Hepatitis a virus vaccine - Google Patents

Hepatitis a virus vaccine Download PDF

Info

Publication number
SI9300421A
SI9300421A SI9300421A SI9300421A SI9300421A SI 9300421 A SI9300421 A SI 9300421A SI 9300421 A SI9300421 A SI 9300421A SI 9300421 A SI9300421 A SI 9300421A SI 9300421 A SI9300421 A SI 9300421A
Authority
SI
Slovenia
Prior art keywords
hepatitis
hav
virus
protein
cell
Prior art date
Application number
SI9300421A
Other languages
English (en)
Slovenian (sl)
Inventor
Robert A Aboud
John G Aunins
Barry C Buckland
Peter A Dephillips
Anna J Hagen
John P Hennessey
Beth Junker
John A Lewis
Oliver Cynthia Newell
Charles J Orella
Robert D Sitrin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SI9300421A publication Critical patent/SI9300421A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI9300421A 1992-08-07 1993-08-06 Hepatitis a virus vaccine SI9300421A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92687392A 1992-08-07 1992-08-07
CN93117633A CN1099798A (zh) 1992-08-07 1993-08-06 甲型肝炎病毒疫苗

Publications (1)

Publication Number Publication Date
SI9300421A true SI9300421A (en) 1994-06-30

Family

ID=36869970

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9300421A SI9300421A (en) 1992-08-07 1993-08-06 Hepatitis a virus vaccine

Country Status (16)

Country Link
EP (1) EP0583142A2 (https=)
JP (1) JPH0748277A (https=)
CN (1) CN1099798A (https=)
AU (1) AU4450093A (https=)
CA (1) CA2103515A1 (https=)
CZ (1) CZ34795A3 (https=)
DZ (1) DZ1706A1 (https=)
FI (1) FI950567A7 (https=)
HU (1) HUT70982A (https=)
MX (1) MX9304803A (https=)
NO (1) NO950483L (https=)
PL (1) PL307402A1 (https=)
SI (1) SI9300421A (https=)
SK (1) SK18495A3 (https=)
WO (1) WO1994003589A2 (https=)
ZA (1) ZA935723B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2096650A1 (en) * 1991-09-18 1993-03-21 Keith E. Langley Hepatitis b vaccine formulation incorporating a bile acid salt
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
CN101618049A (zh) * 1997-10-09 2010-01-06 威尔斯塔特生物公司 使用病毒来治疗赘生物
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
IL145899A0 (en) 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
KR100421386B1 (ko) * 2001-09-22 2004-03-09 엘지전자 주식회사 초고속용 유도 전동기의 회전자
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
DE60327069D1 (de) 2002-04-30 2009-05-20 Oncolytics Biotech Inc Verbesserte reinigungsmethode für viren
GB0304799D0 (en) * 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
WO2005070454A2 (en) * 2004-01-27 2005-08-04 Bharat Biotech International Limited A novel process of hepatitis a vaccine preparation
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CN101816786B (zh) * 2010-04-30 2012-09-05 长春生物制品研究所有限责任公司 一种甲型肝炎灭活疫苗及其制备方法
CN102058882B (zh) * 2010-12-28 2012-12-26 深圳康泰生物制品股份有限公司 一种制备甲型肝炎灭活疫苗的方法
CN103013933B (zh) * 2012-12-14 2014-10-22 北京民海生物科技有限公司 人二倍体狂犬病疫苗病毒液的灭活方法
EP3121268B1 (en) * 2015-07-23 2018-12-26 Grifols, S.A. Methods for purification of a virus produced in vitro and clearance assay for the virus
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
EP3695849A1 (en) * 2019-02-13 2020-08-19 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Method for extracting hepatitis a virus (hav) antigen from cell culture
CN112202628B (zh) * 2020-09-08 2022-09-02 杭州涂鸦信息技术有限公司 一种WiFi模块串口协议自动化测试系统及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296204A (en) * 1978-01-25 1981-10-20 Merck & Co., Inc. Use of motionless mixer as cell culture propagator
US4164566A (en) 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
US5021348A (en) 1979-09-04 1991-06-04 Merck & Co., Inc. Attenuated hepatitis A virus
US4415670A (en) 1980-07-07 1983-11-15 Merck & Co., Inc. Motionless mixer as cell culture propagator
US4301249A (en) * 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
NZ225583A (en) 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
JPH0751513B2 (ja) * 1988-04-28 1995-06-05 国立予防衛生研究所長 Ａ型肝炎ワクチン
CA2047041A1 (en) * 1990-07-18 1992-01-19 John A. Lewis Process for purification of hepatitis-a virus capsids

Also Published As

Publication number Publication date
MX9304803A (es) 1994-05-31
DZ1706A1 (fr) 2002-02-17
ZA935723B (en) 1995-03-22
EP0583142A3 (https=) 1994-04-13
PL307402A1 (en) 1995-05-15
WO1994003589A2 (en) 1994-02-17
CA2103515A1 (en) 1994-02-11
FI950567A0 (fi) 1995-02-09
EP0583142A2 (en) 1994-02-16
CN1099798A (zh) 1995-03-08
NO950483D0 (no) 1995-02-09
FI950567A7 (fi) 1995-04-05
WO1994003589A3 (en) 1994-03-31
HUT70982A (en) 1995-11-28
AU4450093A (en) 1994-02-10
SK18495A3 (en) 1995-11-08
NO950483L (no) 1995-04-07
HU9500417D0 (en) 1995-04-28
JPH0748277A (ja) 1995-02-21
CZ34795A3 (en) 1996-03-13

Similar Documents

Publication Publication Date Title
SI9300421A (en) Hepatitis a virus vaccine
FI117513B (fi) Menetelmä PRRS-viruksen viljelemiseksi ja sen käyttö rokotteissa
Purdy et al. Preliminary evidence that a trpE‐HEV fusion protein protects cynomolgus macaques against challenge with wild‐type hepatitis E virus (HEV)
JP5264843B2 (ja) 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス
CA2197683C (en) Method for preparing an influenza virus, antigens obtained and applications thereof
Gutekunst Latent pseudorabies virus infection in swine detected by RNA-DNA hybridization
PT1427817E (pt) Multiplicação de vírus numa cultura celular
US4525349A (en) Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
Mayor et al. Immunofluorescent, cytochemical, and microcytological studies on the growth of the simian vacuolating virus (SV-40) in tissue culture
Matumoto Multiplication of measles virus in cell cultures
Bruguera et al. Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients
EP2075005B1 (en) Ipv-dpt vaccine
CA1164799A (en) Cell culture of hepatitis a virus
CN120173859A (zh) 无血清全悬浮mdck细胞及其在流感疫苗制备中的应用
US6855535B2 (en) Method of large scale production of Hepatitis A virus
TWI227274B (en) Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same
Duchene et al. Production of poliovirus vaccines: past, present, and future
HRP931103A2 (hr) Cjepivo za virus hepatitisa a
Kodama et al. Studies on L cells persistently infected with polyoma virus: relationship between D particle and other virus-like particles
Gannicliffe et al. Human papovaviruses
HK1062029B (en) Multiplication of viruses in a cell culture
HK1129836B (en) Ipv-dpt vaccine
Barquist et al. 003500 Clinical medicine: 004900 Defense; 010100 Microbiology
Epstein Vaccination against Epstein-Barr virus
Epstein Nuffield Department of Clinical Medicine University of Oxford John Radcliffe Hospital, Oxford OX3 9DU, UK